Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132 | EVP, Chief Commercial Officer | March 04, 2026 | March 06, 2026 |
| Lexeo Therapeutics, Inc.LXEO · Entity 5687 | Director | June 25, 2026 | June 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ALNYLAM PHARMACEUTICALS, INC.
Report date March 04, 2026 · Filed March 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 34,297 |
Ending reported balance
After 2026-03-04 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2026-03-04 · Sale · Disposed 106 · Balance 36,500 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 2 · 2026-03-04 · Sale · Disposed 102 · Balance 36,398 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 3 · 2026-03-04 · Sale · Disposed 215 · Balance 36,183 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 4 · 2026-03-04 · Sale · Disposed 289 · Balance 35,894 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 5 · 2026-03-04 · Sale · Disposed 350 · Balance 35,544 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 6 · 2026-03-04 · Sale · Disposed 767 · Balance 34,777 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 7 · 2026-03-04 · Sale · Disposed 272 · Balance 34,505 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Row 8 · 2026-03-04 · Sale · Disposed 208 · Balance 34,297 F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units. F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement to cover minimum statutory tax withholding obligations upon the vesting of restricted stock units.
F2: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $318.27 to $319.27. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $319.28 to $320.28. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F4: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $320.33 to $321.33. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F5: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $321.34 to $322.31. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F6: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $322.36 to $323.36. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F7: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $323.38 to $324.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F8: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $324.39 to $325.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F9: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $325.40 to $326.21. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Lexeo Therapeutics, Inc.
Report date June 25, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2036-06-24 | Direct | 35,000 |
Reported balance
After 2026-06-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-25 · Grant · Acquired 35,000 · Balance 35,000 F1: 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying the option shall vest, and become exercisable, on the earlier of one year following the grant date or the next annual meeting of stockholders, subject to the Reporting Person's continuous service on such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 11, 2024 Filed Nov 13, 2024 22:34 UTC | Lexeo Therapeutics, Inc. LXEO · Entity 5687 | GrantStock Option (right to buy) · Derivative | 36,000 | $0.00 Strike: $7.95 | $0.00 |
DisclosureSEC source: 0001415889-24-026739 · form4-11132024_101138.xml · derivative · entry 1 Tanguler Tolga · CIK 0001849458 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2034-11-10 F1 · derivative.exercise_date: The shares subject to the option shall vest and become exercisable in equal annual installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 167 | $235.19 | $39,276.73 |
DisclosureSEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 13 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,660 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F14 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $235.10 to $235.73. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 185 | $234.66 | $43,412.10 |
DisclosureSEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 12 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,827 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F13 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $234.06 to $235.04. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 115 | $233.53 | $26,855.95 |
DisclosureSEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 11 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,012 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F12 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $233.00 to $234.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 216 | $232.54 | $50,228.64 |
DisclosureSEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 10 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,127 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F11 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $231.97 to $232.97. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 99 | $231.59 | $22,927.41 |
DisclosureSEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 9 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,343 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $230.92 to $231.78. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 304 | $229.93 | $69,898.72 |
DisclosureSEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 8 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,442 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $229.76 to $230.70. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 266 | $229.06 | $60,929.96 |
DisclosureSEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 7 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,746 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $228.75 to $229.72. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 129 | $228.30 | $29,450.70 |
DisclosureSEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 6 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,012 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $227.72 to $228.71. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 34 | $226.82 | $7,711.88 |
DisclosureSEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 5 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,141 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $226.45 to $227.35. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 18 | $225.55 | $4,059.90 |
DisclosureSEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 4 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,175 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $224.99 to $225.98. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 13 | $224.17 | $2,914.21 |
DisclosureSEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 3 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,193 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $223.92 to $224.43. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 25, 2024 Filed Jun 26, 2024 20:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 59 | $221.71 | $13,080.89 |
DisclosureSEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 2 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,206 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $221.37 to $222.00. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 24, 2024 Filed Jun 26, 2024 20:26 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 3,278 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-24-000066 · edgardoc.xml · nonDerivative · entry 1 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,265 F1 · kind: On February 23, 2022, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting of a positive, statistically significant result on a clinical outcomes endpoint from a Phase 3 clinical study in ATTR amyloidosis with cardiomyopathy, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on June 24, 2024. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 9,279 | $0.00 Strike: $152.61 | $0.00 |
DisclosureSEC source: 0001735276-24-000030 · edgardoc.xml · derivative · entry 2 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,279 Underlying: Common Stock · 9,279 shares Expires 2034-03-01 F3 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the grant date and the remaining shares vesting in equal installments at the end of each successive three-month period thereafter until the fourth anniversary of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:22 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 4,751 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-24-000030 · edgardoc.xml · nonDerivative · entry 1 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,987 F1 · shares: These shares are represented by restricted stock units (RSUs) granted under the Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest over a three-year period, with one third vesting on each of the first, second and third anniversaries of the grant date, subject to the Reporting Persons continuous service with the Issuer as of each such vesting date. F2 · balance_after: The Reporting Person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 4,751 newly awarded RSUs and 5,236 shares of common stock. The Reporting Person also holds 3,333 unvested RSUs that were previously reported in Table II. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 21:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1 | $158.09 | $158.09 |
DisclosureSEC source: 0001735276-24-000020 · edgardoc.xml · nonDerivative · entry 6 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,236 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 21:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 14 | $157.30 | $2,202.20 |
DisclosureSEC source: 0001735276-24-000020 · edgardoc.xml · nonDerivative · entry 5 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,237 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $157.01 to $157.99. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 21:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 100 | $156.38 | $15,638.00 |
DisclosureSEC source: 0001735276-24-000020 · edgardoc.xml · nonDerivative · entry 4 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,251 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $155.96 to $156.91. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 21:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 170 | $155.45 | $26,426.50 |
DisclosureSEC source: 0001735276-24-000020 · edgardoc.xml · nonDerivative · entry 3 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,351 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $154.95 to $155.95. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 28, 2024 Filed Feb 29, 2024 21:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 216 | $154.54 | $33,380.64 |
DisclosureSEC source: 0001735276-24-000020 · edgardoc.xml · nonDerivative · entry 2 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,521 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $153.94 to $154.94. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionRestricted Stock Units · Derivative | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-24-000020 · edgardoc.xml · derivative · entry 7 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 1,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F7 · derivative.exercise_date: On February 27, 2023, the reporting person was granted 5,000 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2024, the first tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4. F7 · derivative.expiration_date: On February 27, 2023, the reporting person was granted 5,000 restricted stock units that vest ratably on each of the first, second and third anniversaries of the Grant Date. On February 27, 2024, the first tranche of restricted stock units from the February 27, 2023 grant vested and was released, as reported on this Form 4. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 21:18 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 1,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-24-000020 · edgardoc.xml · nonDerivative · entry 1 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,737 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 121 | $149.03 | $18,032.63 |
DisclosureSEC source: 0001735276-24-000008 · edgardoc.xml · nonDerivative · entry 4 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,070 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $148.96 to $149.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 519 | $148.24 | $76,936.56 |
DisclosureSEC source: 0001735276-24-000008 · edgardoc.xml · nonDerivative · entry 3 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,191 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $147.88 to $148.83. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 369 | $147.50 | $54,427.50 |
DisclosureSEC source: 0001735276-24-000008 · edgardoc.xml · nonDerivative · entry 2 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,710 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $146.88 to $147.87. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 15, 2024 Filed Feb 20, 2024 21:08 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 3,278 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-24-000008 · edgardoc.xml · nonDerivative · entry 1 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,079 F1 · kind: On February 23, 2022, the reporting person was granted a performance-based stock unit (PSU) under the 2018 Stock Incentive Plan. The shares subject to the PSU vest based on the achievement of three specified performance measures. The shares reported were issued to the reporting person upon vesting of one-third of the shares subject to the PSU based on the issuer publicly reporting $1.5 billion in total annual revenue, as determined by The People, Culture and Compensation Committee of the Issuer Board of Directors on February 15, 2024. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 21:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 103 | $197.08 | $20,299.24 |
DisclosureSEC source: 0001735276-23-000046 · edgardoc.xml · nonDerivative · entry 6 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,801 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 21:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 64 | $195.65 | $12,521.60 |
DisclosureSEC source: 0001735276-23-000046 · edgardoc.xml · nonDerivative · entry 5 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,904 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 195.50 to $196.09. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 21:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 625 | $194.94 | $121,837.50 |
DisclosureSEC source: 0001735276-23-000046 · edgardoc.xml · nonDerivative · entry 4 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,968 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F5 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 194.49 to $195.49. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 21:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 562 | $193.93 | $108,988.66 |
DisclosureSEC source: 0001735276-23-000046 · edgardoc.xml · nonDerivative · entry 3 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,593 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 193.48 to $194.48. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 27, 2023 Filed Apr 28, 2023 21:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 122 | $193.18 | $23,567.96 |
DisclosureSEC source: 0001735276-23-000046 · edgardoc.xml · nonDerivative · entry 2 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,155 F2 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $ 192.47 to $193.47. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| April 26, 2023 Filed Apr 28, 2023 21:55 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantCommon Stock | 3,277 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-23-000046 · edgardoc.xml · nonDerivative · entry 1 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,277 F1 · kind: On February 23, 2022, the reporting person was granted performance-based stock units (PSUs) in connection with the issuer 2021 year-end compensation review. The PSUs vest in separate installments based on the achievement of three specified performance measures as determined by the People, Culture and Compensation Committee of the issuer Board of Directors. The shares reported were issued to the reporting person upon vesting of one-third of the PSUs based on achievement of a corresponding performance measure relating to the issuer public reporting of human proof-of-concept of an investigational therapeutic directed to an extrahepatic target (central nervous system, or CNS). Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantStock Option (right to buy) · Derivative | 10,352 | $0.00 Strike: $190.01 | $0.00 |
DisclosureSEC source: 0001735276-23-000027 · edgardoc.xml · derivative · entry 2 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,352 Underlying: Common Stock · 10,352 shares Expires 2033-02-27 F4 · shares: Represents the time-vested stock option portion of the reporting person's annual equity award granted in 2023 for 2022 performance. F5 · derivative.exercise_date: The stock option vests as to 25% of the shares on the first anniversary of the grant date and as to an additional 6.25% of the shares at the end of each successive three month period thereafter until the fourth anniversary of the grant date. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:21 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | GrantRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-23-000027 · edgardoc.xml · derivative · entry 1 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2026-02-27 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F2 · shares: Represents the time-vested restricted stock unit portion of the reporting person's annual equity award granted in 2023 for 2022 performance. The reporting person also received 10,000 performance stock units as part of their annual equity award that will vest upon the achievement of three specific performance conditions (subject to a one year minimum vesting period), which will be reported on a Form 4 as to the performance stock units allocated to each performance condition if and when each performance condition is met and the performance stock units vest. F3 · derivative.exercise_date: The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date. F3 · derivative.expiration_date: The restricted stock units vest ratably in three installments, with one third vesting on each of the first, second and third anniversaries of the grant date. Read SEC document |
| February 03, 2023 Filed Feb 3, 2023 22:45 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 953 | $233.31 | $222,344.43 |
DisclosureSEC source: 0001735276-23-000006 · edgardoc.xml · nonDerivative · entry 10 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F5 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022. F10 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $233.02 to $233.81. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 03, 2023 Filed Feb 3, 2023 22:45 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 1,293 | $232.53 | $300,661.29 |
DisclosureSEC source: 0001735276-23-000006 · edgardoc.xml · nonDerivative · entry 9 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 953 F5 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022. F9 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $231.94 to $232.90. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 03, 2023 Filed Feb 3, 2023 22:45 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 865 | $231.35 | $200,117.75 |
DisclosureSEC source: 0001735276-23-000006 · edgardoc.xml · nonDerivative · entry 8 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,246 F5 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022. F8 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $230.90 to $231.90. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 03, 2023 Filed Feb 3, 2023 22:45 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 185 | $230.20 | $42,587.00 |
DisclosureSEC source: 0001735276-23-000006 · edgardoc.xml · nonDerivative · entry 7 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,111 F5 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022. F7 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $229.87 to $230.62. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 03, 2023 Filed Feb 3, 2023 22:45 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 128 | $227.68 | $29,143.04 |
DisclosureSEC source: 0001735276-23-000006 · edgardoc.xml · nonDerivative · entry 6 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,296 F5 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022. F6 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $227.63 to $228.38. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:45 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 4 | $227.38 | $909.52 |
DisclosureSEC source: 0001735276-23-000006 · edgardoc.xml · nonDerivative · entry 5 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,424 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:45 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 561 | $226.62 | $127,133.82 |
DisclosureSEC source: 0001735276-23-000006 · edgardoc.xml · nonDerivative · entry 4 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,428 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F4 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $226.23 to $227.12. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:45 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 963 | $225.80 | $217,445.40 |
DisclosureSEC source: 0001735276-23-000006 · edgardoc.xml · nonDerivative · entry 3 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,989 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F3 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $225.21 to $226.20. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 02, 2023 Filed Feb 3, 2023 22:45 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 73 | $223.97 | $16,349.81 |
DisclosureSEC source: 0001735276-23-000006 · edgardoc.xml · nonDerivative · entry 2 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,952 F1 · kind: Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of restricted stock units reported in this form. F2 · price: The price reported represents the weighted average sales price of shares sold in multiple transactions at prices ranging from $223.42 to $224.25. The reporting person will provide to the issuer, any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:45 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionRestricted Stock Units · Derivative | 5,025 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001735276-23-000006 · edgardoc.xml · derivative · entry 11 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,025 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ALNY common stock. F12 · derivative.exercise_date: On February 1, 2021 the reporting person received 10,051 restricted stock units, one-half of which vested on the first anniversary of the grant date, and one-half of which vested on the second anniversary of the grant date (February 1, 2023). F12 · derivative.expiration_date: On February 1, 2021 the reporting person received 10,051 restricted stock units, one-half of which vested on the first anniversary of the grant date, and one-half of which vested on the second anniversary of the grant date (February 1, 2023). Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 22:45 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | Exercise / conversionCommon Stock | 5,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001735276-23-000006 · edgardoc.xml · nonDerivative · entry 1 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,025 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 05, 2022 Filed Aug 5, 2022 20:15 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 104 | $225.15 | $23,415.60 |
DisclosureSEC source: 0001735276-22-000067 · edgardoc.xml · nonDerivative · entry 12 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022. Read SEC document |
| August 05, 2022 Filed Aug 5, 2022 20:15 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 5 | $224.00 | $1,120.00 |
DisclosureSEC source: 0001735276-22-000067 · edgardoc.xml · nonDerivative · entry 11 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104 F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022. Read SEC document |
| August 05, 2022 Filed Aug 5, 2022 20:15 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 105 | $220.95 | $23,199.75 |
DisclosureSEC source: 0001735276-22-000067 · edgardoc.xml · nonDerivative · entry 10 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109 F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022. Read SEC document |
| August 05, 2022 Filed Aug 5, 2022 20:15 UTC | ALNYLAM PHARMACEUTICALS, INC. ALNY · Entity 3132 | SaleCommon Stock | 99 | $219.53 | $21,733.47 |
DisclosureSEC source: 0001735276-22-000067 · edgardoc.xml · nonDerivative · entry 9 Tanguler Tolga · CIK 0001849458 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214 F2 · kind: These sales were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 2, 2022. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.